Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hemorrhage and VEGF expression in a case of primary CNS lymphoma.

Literature DB >> 12160141

Hemorrhage and VEGF expression in a case of primary CNS lymphoma.

James Rubenstein¹, Nancy Fischbein, Ken Aldape, Eric Burton, Marc Shuman.

Abstract

Hemorrhage at presentation in primary CNS lymphoma is exceedingly rare. We describe a patient with primary CNS lymphoma who presented with seizures and was found to have an intracerebral hemorrhage which prompted a cerebral angiogram. Ultimately pathologic evaluation of the lesion revealed a highly cellular B-cell lymphoma with marked hypervascularity and intense expression of vascular endothelial growth factor (VEGF). A review of four other recent cases of primary CNS lymphoma at our institution revealed less-intense VEGF immunoreactivity. This is the first report of VEGF expression in primary CNS lymphoma. The potential significance of VEGF expression with respect to the biology of this tumor is discussed.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2002 PMID： 12160141 DOI： 10.1023/a:1015887312455

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

11 in total

1. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

Authors: P Salven; A Orpana; L Teerenhovi; H Joensuu
Journal: Blood Date: 2000-12-01 Impact factor: 22.113

2. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.

Authors: S Y Cheng; M Nagane; H S Huang; W K Cavenee
Journal: Proc Natl Acad Sci U S A Date: 1997-10-28 Impact factor: 11.205

3. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.

Authors: P Salven; L Teerenhovi; H Joensuu
Journal: Blood Date: 1997-10-15 Impact factor: 22.113

4. The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.

Authors: P P Molnár; B P O'Neill; B W Scheithauer; D R Groothuis
Journal: Neuro Oncol Date: 1999-04 Impact factor: 12.300

Review 5. Glucocorticoid treatment of primary CNS lymphoma.

Authors: M Weller
Journal: J Neurooncol Date: 1999-07 Impact factor: 4.130

6. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

Authors: W T Bellamy; L Richter; Y Frutiger; T M Grogan
Journal: Cancer Res Date: 1999-02-01 Impact factor: 12.701

7. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor.

Authors: J D Heiss; E Papavassiliou; M J Merrill; L Nieman; J J Knightly; S Walbridge; N A Edwards; E H Oldfield
Journal: J Clin Invest Date: 1996-09-15 Impact factor: 14.808

Review 8. Primary central nervous system lymphoma.

Authors: H A Fine; R J Mayer
Journal: Ann Intern Med Date: 1993-12-01 Impact factor: 25.391

Review 9. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with particular reference to calcification haemorrhage and cyst formation.

Authors: C N Jenkins; I R Colquhoun
Journal: Clin Radiol Date: 1998-06 Impact factor: 2.350

9. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.

Authors: Yasuo Sugita; Yukari Takase; Daisuke Mori; Osamu Tokunaga; Akihiko Nakashima; Minoru Shigemori
Journal: J Neurooncol Date: 2006-11-11 Impact factor: 4.506

10. Emergent management with favorable outcome of an unusual presentation of a primary central nervous system lymphoma in an immunocompetent patient.

Authors: Junko Matsuyama
Journal: J Neurosci Rural Pract Date: 2014-01

Hemorrhage and VEGF expression in a case of primary CNS lymphoma.

1. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

2. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.

3. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.

4. The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.

Review 5. Glucocorticoid treatment of primary CNS lymphoma.

6. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

7. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor.

Review 8. Primary central nervous system lymphoma.

Review 9. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with particular reference to calcification haemorrhage and cyst formation.

10. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.

1. A haemorrhagic, contrast-enhancing lesion of the basal ganglia.

Review 2. Current Clinical Brain Tumor Imaging.

3. Angiogenesis in primary central nervous system lymphoma (PCNSL).

4. Post-traumatic basal ganglia haemorrhage in a child with primary central nervous system lymphoma.

5. Post-treatment T1 shortening in primary CNS lymphoma.

6. MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.

7. Intracranial hemorrhage in adult patients with hematological malignancies.

8. Incidence and etiology of cerebrovascular disease in patients with malignancy.

9. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.

10. Emergent management with favorable outcome of an unusual presentation of a primary central nervous system lymphoma in an immunocompetent patient.